Our team has worked tirelessly for more than a decade to evolve and master our understanding of the rich, complex information encoded in circulating nucleosomes.

Nucleosomics™ is currently being used for cancer applications in veterinary medicine and we are continuing to expand our technology in human medicine through early clinical trials in various cancers, COVID-19, sepsis and beyond.

We believe that our focus on innovation, robust assay development pipeline, and diverse intellectual property portfolio positions us to become a significant player in this cutting-edge field of science.

For more information about VolitionRx Corp. please email Scott Powell